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The rising prevalence of allergies represents an increasing socioeconomic burden. A
detailed understanding of the immunological mechanisms that underlie the development of
allergic disease, as well as the processes that drive immune tolerance to allergens, will be
instrumental in designing therapeutic strategies to treat and prevent allergic disease.
Improved characterization of individual patients through the use of specific biomarkers and
improved definitions of disease endotypes are paving the way for the use of targeted
therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and
biologic therapies that target key molecules driving the Th2 response are already used in
the clinic, and a wave of novel drug candidates are under development. In-depth analysis of
the cells and tissues of patients treated with such targeted interventions provides a wealth of
information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim
to deliver an overview of the current state of specific inhibitors used in the treatment of
allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the
roles of these molecules in immunological mechanisms of allergic disease.
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Immunological mechanisms of allergy  
and tolerance
Allergic sensitization and type I and IV hypersensitivity reactions. 
Allergies develop as a result of an immune response to distinct 
environmental protein antigens, called allergens. In recent years, 
substantial progress has been made in elucidating mechanisms 
that drive the initiation and persistence of allergic reactions. 
Development of allergic diseases starts with a sensitization phase 
(Figure 1). Key processes driving allergic sensitization include 
activation and maturation of dendritic cells (DCs) upon contact 
with allergens, epithelial alarmins, and infectious agents, fol-
lowed by clonal expansion of allergen-specific Th2 cells that are 
polarized toward producing type 2 cytokines, including IL-4, IL-5, 
IL-9, IL-13, IL-25, IL-31, IL-33, and thymic stromal lymphopoietin 
(TSLP) (1). Th2 cells induce class switch recombination of B cells to 
the IgE isotype and differentiation to IgE-producing plasma cells. 
IgE can bind to the high-affinity IgE receptor FcεRI on basophils 
and mast cells. Moreover, IgE can also enhance allergen uptake 
and presentation through so-called facilitated antigen presenta-
tion (2, 3). These processes form the basis of allergic sensitization.
Subsequent exposure to the culprit allergen can trigger IgE- 
mediated FcεRI cross-linking on mast cells and basophils, lead-
ing to a type I hypersensitivity reaction. During the early phase 
of this reaction, which starts within minutes after allergen expo-
sure, mast cells and/or basophils degranulate and release a range 
of preformed and newly synthesized mediators including his-
tamine, leukotrienes, heparin, and several proteases, as well as 
cytokines and growth factors such as TNF-α and VEGFA (4). After 
2 to 6 hours of exposure, the late phase of the reaction manifests, 
characterized by edema, erythema in skin, and airway narrowing 
and mucus secretion in the airways. These symptoms are caused 
by the recruitment and activation of Th2 cells, eosinophils, baso-
phils, and tissue- resident mast cells. Persistent allergen exposure 
can produce a chronic phase of inflammation that represents a 
distinct Th2 type of type IV hypersensitivity (5). Classical type IV 
hypersensitivity denotes tuberculin-type hypersensitivity with 
the involvement of Th1 cells. In allergic inflammation a cellular 
late-phase response develops, characterized by tissue inflamma-
tion with eosinophils, Th2 cells, and type 2 innate lymphoid cells 
(ILC2s); remodeling of vasculature and smooth muscle cells; and 
extracellular matrix formation and fibrosis (4, 5). In the clinical 
setting, this chronic inflammation prevails and forms the basis for 
the main tissue inflammation mechanisms referred to as Th2 or 
type 2 inflammation in asthma, atopic dermatitis (AD), chronic rhi-
nosinusitis (CRS) with nasal polyps, and allergic rhinitis. Notably, 
approximately 20% of pediatric and adult AD patients and 10% to 
20% of pediatric and 50% of adult asthma patients show a non-
allergic and non- eosinophilic phenotype. Most of the CRS without 
nasal polyps patients also fall into this non–type 2 category. So far, 
these non–type 2 diseases have not been efficiently targeted with 
biologics, and their pathogenetic mechanisms are associated with 
a broad range of environmental and/or host factors, such as smok-
ing, exposure to pollutants, work-related agents, chronic infec-
tions, and obesity (6).
Mechanisms of immune tolerance to allergens. In recent years, 
substantial efforts have been made to improve the classification 
of patients suffering from allergic disease in order to facilitate 
the development of personalized medicine. A key concept in 
this regard comes from the determination of so-called disease 
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injection induced the cat allergen– blocking antibody effect within 
a week to the same extent as did AIT (28). Knowledge obtained 
from these studies paved the way for the development of diagnos-
tic tools and innovative drugs, particularly biologics that specifical-
ly target select mediators of allergic immune responses (7, 27, 29, 
30). To date there is no direct evidence that any of the biologics 
discussed in this Review induce allergen tolerance; however, their 
usage together with immune tolerance–inducing AIT is open for 
further studies.
Targeting the mediators of the allergic response
Improved understanding of the immunological mechanisms 
that regulate allergy development and allergen tolerance allows 
a systematic strategy for drug design aimed at targeting specific 
molecules with a known or suspected role in these processes. The 
feedback from preclinical work and clinical trial results provide an 
invaluable data resource to further elucidate these mechanisms. 
Here, we describe the major strategies aimed at prevention and 
treatment of allergic disease and discuss the insights they provide 
into the immunological mechanisms of allergy and tolerance.
Recent advances in the field of therapeutic antibodies have 
led to the development of a wide range of biologic drug candi-
dates (mostly mAbs) for the treatment of allergic diseases (listed 
in Table 1). These can be broadly grouped into two distinct groups: 
(a) biologics targeting cytokines and cytokine receptors, and (b) 
biologics targeting soluble and membrane-bound IgE.
endotypes, which describe a subtype of a disease condition 
defined by distinct pathophysiological mechanisms, in contrast 
to disease phenotypes, which define disease characteristics 
without implying a mechanism. Identification of biomarkers 
that accurately and objectively examine pathogenic process-
es and responses to therapeutic interventions is critical for the 
development of individual therapies. The term “theratype” has 
been coined to describe subsets of patients that respond well to 
a certain therapeutic intervention (7–12).
The induction of immune tolerance involves molecular mech-
anisms of anergy, deletion, suppression, immune privilege, and 
ignorance. This Review mainly focuses on immunological mech-
anisms of peripheral tolerance to allergens. Various models have 
been used to study the mechanisms that drive immune tolerance 
to allergens. These include the in-depth analysis of immunologi-
cal parameters in allergic patients treated with allergen-specific 
immunotherapy (AIT) and in healthy individuals who are chron-
ically exposed to high-doses of allergens, such as cat owners and 
nonallergic beekeepers (13, 14). Early desensitization of mast cells 
and basophils (15), induction of regulatory T (13, 16–18) and B 
cells (19–22), anergy in Th2 cells, and probably apoptosis of highly 
activated Th2 cells (23), suppression of eosinophil activation and 
migration (24), and production of allergen- specific IgG4 antibod-
ies (25, 26) are key processes in the development of immune toler-
ance in response to AIT (27). In humans most of these findings are 
correlative, but a recent study reported that anti–Fel d 1–IgG4 mAb 
Figure 1. Key cellular and molecular players in allergic sensitization. Allergens and pathogens that have passed the skin or mucosal epithelium are 
phagocytosed by antigen-presenting cells (APCs). These APCs mature as a result of cytokines produced by epithelial cells, then migrate to draining lymph 
nodes, where they present allergen-derived peptides to CD4+ T cells and induce differentiation to Th2 cells. ILC2s are also activated by epithelial cell–
derived cytokines such as IL-25, IL-33, and TSLP. Th2 cells and ILC2s produce type 2 cytokines such as IL-4, IL-13, IL-5, and IL-9. IL-4 and IL-13 drive IgE class 
switch recombination of B cells, leading to allergen-specific IgE production. Allergen-specific IgE binds to FcεRI on mast cells and basophils. IL-4, IL-9, and 
IL-13 promote mucus secretion by goblet cells, whereas IL-5 is instrumental in eosinophil recruitment. TCR, T cell receptor.
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unsuccessful studies cannot rule out any relevant molecular 
mechanisms, because these drugs depend on many pharmacody-
namic factors, such as dose, affinity, half-life, etc. A clinical study 
in 2000 showed that a single dose of anti–IL-5 mAb decreased 
blood eosinophils for up to 16 weeks and sputum eosinophils at 4 
weeks, which has considerable therapeutic potential for asthma 
and allergy. However, the data did not support the treatment effect 
of anti–IL-5 mAb for late asthmatic response and airway hyperre-
sponsiveness (38).
Dupilumab’s use for other applications is currently being 
explored. Promising results have been obtained for patients with 
chronic sinusitis and nasal polyposis (39, 40). A recent case report 
described the successful treatment of a recalcitrant bullous pem-
phigoid patient with dupilumab (41). Several other biologics have 
been developed to target IL-4Rα (42, 43). Among these is pitrak-
inra (trade name Aerovant), a biologic drug that, in contrast to 
other biologics targeting the IL-4/IL-13 pathway, is not an mAb. 
Pitrakinra is a recombinant IL-4 that contains two targeted point 
mutations and functions as an antagonist of IL-4Rα (44, 45). 
Thus, its expected mode of action is analogous to that of dupi-
lumab. Inhalation treatment of asthma patients with pitrakinra 
did not show an overall significant improvement of asthma exac-
erbations (45). Interestingly, a subgroup analysis revealed that 
patients with a specific SNP (rs8832GG) in the 3′-untranslated 
region of the IL4RA gene did significantly improve exacerbations 
Targeting classical Th2 effectors using IL-4/IL-13 
interference
IL-4 and IL-13 are structurally and functionally related cytokines 
that display approximately 25% sequence homology. Both are 
composed of four α-helix bundles. These cytokines are pivotal 
for both IgE sensitization and late-phase allergic responses. IL-4 
and IL-13 share many functional characteristics, including their 
capacity to induce IgE class switch recombination (albeit only in 
humans, as IL-13 cannot induce IgE in mice), airway hyperreac-
tivity, mucus production, goblet cell hyperplasia, smooth muscle 
cell contraction, and airway remodeling (1, 31).
Both IL-4 and IL-13 are produced by Th2 cells, basophils, 
mast cells, and NKT cells. ILC2s can also produce small amounts 
of IL-4, but their capacity to produce IL-13 is much higher (1, 32). 
IL-4 signals through receptors consisting of heterodimers of the 
IL-4Rα and the common Υ chain and through receptors compris-
ing a heterodimer of IL-4Rα chain and IL-13Rα1 or IL-13Rα2, a sig-
naling pathway it shares with IL-13 (Figure 2 and ref. 1). The fact 
that IL-4 and IL-13 share a receptor explains their large function-
al overlap. Several drugs targeting IL-4, IL-13, and their common 
receptor have been developed. However, so far only dupilumab, 
an mAb targeting IL-4Rα, has proven efficacious, and it has been 
licensed for the treatment of AD (33) and asthma (34–37). These 
findings suggest that inhibiting both IL-4 and IL-13 is necessary 
for clinically successful results, but it should be noted here that 
Table 1. Biologic drug candidates for the treatment of allergic diseases
Target Biologic Type of drug Effect on disease
IL-4Rα Dupilumab mAb Efficacious for atopic dermatitis and asthma
IL-4Rα Pitrakinra Mutated IL-4 molecule No significant improvement of asthma exacerbations but efficacious in a subgroup of asthma 
patients with a specific SNP in the IL4RA gene
IL-13 Lebrikizumab mAb No significant improvement of asthma exacerbations but efficacious in a subgroup of patients  
with high serum periostin levels
IL-4/IL-13 QBX258 Combination of mAbs  
targeting IL-4 and IL-13
No results published yet
IL-5 Mepolizumab mAb Efficacious for treatment of severe eosinophilic asthma; reduced need for surgery in severe nasal 
polyposis patients; reduction in blood and esophageal eosinophilia in EoE patients
IL-5 Reslizumab mAb Efficacious for treatment of severe eosinophilic asthma
IL-5Rα Benralizumab mAb Efficacious for treatment of severe eosinophilic asthma
IL-9 Enokizumab mAb No significant improvement of asthma symptoms
IL-31 BMS-981164 mAb No results published yet
IL-31 Nemolizumab mAb Significantly reduced the level of pruritus in patients with moderate to severe AD
TSLP Tezepelumab mAb Efficacious for treatment of allergic asthma; no significant improvement in atopic dermatitis patients
IL-33 Etokimab mAb Trials ongoing for treatment of peanut allergy, atopic dermatitis, allergic asthma, chronic 
rhinosinusitis with nasal polyps
IL-33 MEDI3506 mAb Trial ongoing for treatment of chronic obstructive pulmonary disease
IL-33R (ST2) RG 6149/AMG 282 mAb Trial in chronic rhinosinusitis with nasal polyps completed, no results published; trial ongoing  
for treatment of chronic obstructive pulmonary disease
IgE Omalizumab mAb Efficacious for treatment of allergic asthma and spontaneous urticaria
IgE Ligelizumab mAb Efficacious for treatment of allergic asthma
IgE Quilizumab mAb Reduction in serum IgE but no significant reduction in asthma exacerbations
IgE MEDI4212 mAb Rapid but short-lived reduction in IgE
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IL-4 (dectrekumab, also known as VAK 694) 
and anti–IL-13 (QAX576, listed under the 
name QBX258) agents. This approach has 
the potential to tackle the redundancy prob-
lem, but results have not yet been published.
Interfering with eosinophil 
responses by targeting IL-5
IL-5 is produced by Th2 cells, mast cells, 
NKT cells, activated eosinophils, and 
ILC2s (50–53). It binds to IL-5R, a heterod-
imeric receptor composed of an IL-5Rα 
subunit responsible for binding IL-5 and 
the common β chain responsible for sig-
naling. IL-5R is expressed on eosinophils, 
basophils, mast cells, and B cells (Figure 
2). The common β chain is also responsible 
for IL-3 and GM-CSF signaling (1). Eosin-
ophils inflict tissue damage by degranu-
lating and secreting a range of mediators 
including histamine, arylsulfatase, eosino-
phil peroxidase, and others (54). Because 
of its potent induction of eosinophil activa-
tion, survival, and proliferation, IL-5 con-
tributes substantially to the development 
of allergic airway inflammation in asthma 
(1, 55). This also makes it an attractive tar-
get for therapeutic intervention.
Several biologics directly target IL-5 
itself (mepolizumab and reslizumab) or 
IL-5Rα (benralizumab) (55). All three drugs 
were found to reduce the rate of asthma 
exacerbations in patients with severe eosino-
philic asthma by approximately half and are 
now approved for the treatment of eosino-
philic asthma (56–61). Long-term intrave-
nous application of reslizumab produced 
sustained improvements in lung function 
and asthma exacerbations for up to 2 years in 
patients with moderate to severe eosinophilic 
asthma (62).
Identification of accurate predictive 
biomarkers to identify which patients will 
respond to therapy will help to further 
improve the success of treatment with such IL-5–targeting biolog-
ics. Patients with a count of ≥150 eosinophils per microliter dis-
played the strongest reduction in asthma exacerbation upon treat-
ment with mepolizumab (63). Anti–IL-5 or anti–IL-5Rα therapy 
was also investigated in other patient groups that suffer from 
eosinophil- associated diseases. Patients with eosinophilic nasal 
polyposis who were treated with mepolizumab every 4 weeks for 
25 weeks were less likely to require surgery as a treatment for 
their condition (64). Another condition that may benefit from 
anti–IL-5 therapy is eosinophilic esophagitis (EoE). Anti–IL-5 
therapy led to marked decreases in peripheral blood and esoph-
ageal eosinophilia in EoE patients and improved clinical out-
comes in both adults and children (65–67) in some studies, but 
(45). Therefore, this genetic variant could be considered a bio-
marker for patients with a high likelihood of responding to this 
treatment. Contemporaneous with this trial, a successful phase 
II trial with lebrikizumab (an anti–IL-13 mAb) for treatment of 
asthma indicated the secreted protein periostin as a biomarker 
for patient selection (46); however, lebrikizumab did not show 
efficacy in a multicenter phase III trial (47).
Several biologics that directly target IL-4 or IL-13, rather than 
their receptors, have failed to meet their clinical endpoints in asth-
ma (43, 48, 49). The main reason for this most likely stems from the 
large degree of redundancy in biological function between IL-4 and 
IL-13. A recent study (NCT01479595; ClinicalTrials.gov) assessed 
the efficacy of treating asthma patients with a combination of anti–
Figure 2. Receptors of key cytokines involved in Th2 responses. (A) IL-4 and IL-13 partially share their 
receptor complexes. One of the IL-4 receptor complexes and the IL-9 receptor both use the common 
γ chain (γc) for signaling. γc is also involved in IL-2, IL-7, IL-15, and IL-21 signaling (not shown). (B) IL-5 
signals through a heterodimer consisting of IL-5Rα and the common β chain (βc), which is also involved 
in IL-3 and GM-CSF signaling. (C) The receptors for TSLP, IL-25, and IL-33 do not share any subunits. (D) 
The IL-31 receptor is composed of IL-31 receptor α (IL-31RA) and oncostatin M receptor β (OSMR).
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82). It has been shown to promote Th2-driven inflammation 
(83). The main property of IL-31 that gives it a unique role is its 
ability to induce pruritus in conditions such as AD (82). This is 
most likely related to the fact that the IL-31 receptor complex is 
expressed at high levels on dorsal root ganglia, where the cell 
bodies of cutaneous neurons are located.
Currently two mAbs that target IL-31 signaling are under 
development. BMS-981164 binds IL-31, while nemolizumab is 
directed against IL-31Rα (82). A phase I trial of BMS-981164 in AD 
patients was completed in 2015 (NCT01614756), but no results 
have been published yet. A phase II trial demonstrated that sub-
cutaneous monthly treatment with nemolizumab significantly 
reduced the level of pruritus after 3 months in patients with mod-
erate to severe AD (84). A later study showed that this beneficial 
effect was maintained for up to 64 weeks (85). Interestingly, an 
experiment in which healthy controls and AD patients were chal-
lenged with topical IL-31 by skin prick testing showed no direct 
induction of itch at the provocation site in most individuals, while a 
late-onset itch response, with a delay of over 2 hours, was reported 
by 9 of 30 subjects. This suggests that IL-31 may exert its pruritic 
effects indirectly through keratinocyte activation rather than 
directly through interaction with cutaneous nerves (86).
Targeting IL-25–, IL-33–, and TSLP-mediated 
epithelium–immune cell interactions
Epithelial cells are instrumental in orchestrating allergic immune 
responses. They are an important source of the Th2- inducing 
cytokines IL-25, IL-33, and TSLP (87). Considerable efforts 
have been made to elucidate the distinct roles of IL-25, IL-33, 
and TSLP in both early and late phases of allergic responses. 
Exposure to allergens, infections, or tissue damage can pro-
mote the release of these cytokines from the epithelium. Early 
priming of the allergen- specific immune responses with these 
cytokines may play an important role in the development of Th2 
priming by DCs and type 2 ILCs. Decreased production of these 
cytokines represents an important target for the priming of type 
2 immune responses as discussed below. Currently, IL-33 and 
TSLP are promising targets, but IL-25–related studies are not 
ongoing on a large scale. This may be due to more exhaustive 
effects of IL-33 and TSLP in in vitro and in vivo studies com-
pared with IL-25, although further studies are needed (88).
IL-25. IL-25 (also referred to as IL-17E) is produced by epithelial 
cells in the gut, lung, and sinus, as well as by Th2 cells, basophils, 
mast cells, and eosinophils (1, 89). Recent studies demonstrated 
that intestinal tuft cells constitutively produce IL-25 to sustain 
ILC2 homeostasis in the murine lamina propria (90). IL-25 binds 
to a heterodimeric receptor consisting of IL-17RA and IL-17RB 
(Figure 2). IL-25 induces secretion of IL-4, IL-5, and IL-13 from 
not recent ones (68). Identification of biologic-responsive EoE 
endotypes and investigation of biologics combined with other 
therapies may help elucidate a role for biologics in EoE (69).
Interfering in IL-9–mediated Th2 and mast cell 
responses
IL-9 is produced by Th2 cells, ILC2s, Th9 cells, and granulocytes 
(including basophils, eosinophils, and possibly neutrophils), as 
well as mast cells (70–76). It signals through the IL-9 receptor 
complex, comprising an IL-9Rα chain and the common γ chain 
(γc), which is expressed on B and T cells, epithelial cells, and mast 
cells (Figure 2 and ref. 1). IL-9 plays a role in allergic disease by 
promoting IgE production by B cells, chemokine production and 
mucus secretion by epithelial cells, and mast cell proliferation 
(77, 78). The anti–IL-9 mAb enokizumab (MEDI528) has been 
evaluated in moderate to severe asthma but failed to demon-
strate an improvement in any of the trials (79). The impressive 
impact of IL-9 in mouse models was not replicated in human 
asthma. Further studies could possibly identify subgroups of 
patients with distinct asthma endotypes that may benefit from 
anti–IL-9 therapy. Anti–IL-9 could also be considered in the con-
text of a combination therapy together with AIT: OVA-sensitized 
mice treated with an oral immunotherapy regimen and anti–
IL-9 showed significant reductions in allergic symptoms, OVA- 
specific IgE levels, and eosinophil counts, as well as reduced Th2 
responses and increased FoxP3 and IL-10 expression (80).
Fighting the itch response by targeting IL-31
IL-31 is produced mainly by Th2 cells and to a lesser extent 
by CD8+ T cells. It signals through a heterodimeric receptor 
consisting of IL-31Rα and oncostatin M receptor β, which is 
expressed by keratinocytes, epithelial cells, eosinophils, baso-
phils, monocytes, and dorsal root ganglia (Figure 2 and refs. 81, 
Figure 3. Targeting IgE and IgE production. Total B cell depletion using the 
anti-CD20 antibody rituximab will target all B cells. Quilizumab targets the 
IgE BCR, leading to depletion of B cells and plasmablasts expressing IgE. 
Omalizumab targets free IgE, while the B cells and plasma cells produc-
ing IgE are not affected. MEDI4121 targets both membrane IgE and free 
IgE. The use of IgE-targeting biologics is aimed at reducing the amount 
of available allergen-specific IgE that facilitates mast cell and basophil 
degranulation and antigen presentation.
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Th2 cells and induces IL-5 and IL-13 secretion from ILC2s (89). 
Therefore, IL-25 is a promising drug target for allergic disease. 
Several studies have demonstrated the potential of IL-25 neutral-
ization in the context of allergic airway inflammation and CRS 
with nasal polyps, but human therapeutics targeting IL-25 are not 
yet in clinical development (91, 92).
Neutralization of IL-25 during the sensitization phase in 
a murine model of allergic airway inflammation significantly 
reduced IL-5 and IL-13 production, reduced eosinophil inflam-
mation and IgE production, and prevented allergic airway hyper-
responsiveness (AHR). When administered during the challenge 
phase, anti–IL-25 could also prevent AHR, indicating that IL-25 
may also play a role during the effector phase of the allergic 
response (93).
TSLP. TSLP is a member of the IL-2 cytokine family that is 
produced by epithelial cells of the skin, gut, and lung (94, 95). 
Basophils, mast cells, and DCs have also been shown to produce 
TSLP (96–98). TSLP has two isoforms, of which the short isoform 
is constitutively expressed, while the long isoform is released in 
response to pathogen exposure, TLR engagement, and stimu-
lation with cytokines such as IL-4, IL-13, IL-1β, and TNF-α. The 
heterodimeric receptor for TSLP, which is composed of the TSLP 
receptor (TSLPR) and IL-7Rα, is expressed by DCs, monocytes, B 
cells, mast cells, and ILC2s (Figure 2 and ref. 99). DCs and ILCs 
are considered prime target cells for TSLP in the context of allergic 
responses (100–102). TSLP-stimulated DCs upregulate OX40L, 
CD80, and CD86 and induce Th2 differentiation from naive 
CD4+ T cells (103). Since TSLP acts on DCs that prime Th2 cells, 
blocking TSLP is expected to reduce the development or enhance-
ment of Th2 responses. TSLP is upregulated in airways of asthma 
patients, and it was found that an SNP in the TSLP locus was asso-
ciated with protection from asthma (104, 105).
The TSLP-targeting therapeutic antibody tezepelumab (AMG 
157) is currently under investigation for the treatment of asthma 
and AD. A phase I trial in 31 patients with mild allergic asthma 
showed that three monthly doses of tezepelumab attenuated most 
measures of allergen-induced early and late asthmatic responses. 
This was associated with decreases in blood and sputum eosino-
phils and exhaled nitric oxide (106). In a phase II study of tezepe-
lumab for the treatment of AD, improvements over placebo were 
not statistically significant (107). A phase II trial with a duration of 
1 year assessing the efficacy and safety of monthly treatment with 
tezepelumab in patients with uncontrolled asthma showed a signif-
icant reduction in asthma exacerbations as well as improved lung 
function. This clinical improvement was independent of eosinophil 
counts at baseline (108). Tezepelumab is also currently being tested 
in combination with AIT with the aim of enhancing the efficacy of 
immunotherapy in cat-allergic patients (NCT02237196). These 
results indicate that anti-TSLP therapy may be effective for the 
treatment of asthma.
IL-33. IL-33 is a member of the IL-1 cytokine family that is 
produced by epithelial cells (109). Its activity is significantly 
increased upon proteolytic cleavage by elastase or cathepsin G (1, 
110). IL-33 signals through a heterodimeric receptor comprising 
ST2 and IL-1 receptor accessory protein (IL-1RAP), the latter of 
which is expressed on mast cells, macrophages, hematopoietic 
stem cells, eosinophils, ILC2s, a subset of Th2 cells, and NKT cells 
(Figure 2 and refs. 1, 110). IL-33 plays a pivotal role in allergic sen-
sitization through its induction of Th2 responses (111), and is an 
important player in DC responses to house dust mites (112). IL-33 
and ST2 have been identified as susceptibility loci for asthma. A 
recently identified subset of Th2 cells, called Th2A cells, included 
all allergen-specific Th2 cells in a cohort of peanut-allergic indi-
viduals. These Th2A cells displayed upregulated ST2 expression 
and produced IL-4 and IL-5 upon IL-33 stimulation (113). Soluble 
ST2 functions as a decoy receptor that suppresses IL-33–mediated 
responses. Recent data showed that IL-33–mediated allergic sen-
sitization in a murine model for gastrointestinal allergy occurred 
independently of TSLP, while TSLP-driven allergic disease could 
not be induced in mice deficient in the IL-33 receptor, indicating 
that IL-33 functions independently or downstream of TSLP. Inter-
estingly, loss of IL-33 expression ameliorated allergic symptoms 
even after sensitization, indicating that IL-33 may be an important 
target in both prevention and treatment of allergies (114).
Therapeutic strategies aimed at targeting IL-33 are being 
explored for their potential in treatment of allergies. Neutral-
izing IL-33 using subcutaneous injection of an anti–IL-33 mAb 
significantly improved AD-like symptoms in a murine model 
of 2,4-dinitrochlorobenzene–induced AD, as demonstrated by 
reduced tissue eosinophil and mast cell counts and reduced 
serum IgE levels (115). Therapeutic antibodies targeting IL-33 
(etokimab/ANB020 and MEDI350) or the IL-33 receptor ST2 
(RG 6149/AMG 282) are currently under development. Clinical 
trials are ongoing for the use of etokimab in AD, peanut allergy, 
and allergic asthma. A phase IIa proof-of-concept study on the 
use of etokimab in peanut allergy showed that a single dose of 
300 mg etokimab improved tolerance to an oral challenge in 6 
of 13 patients who exhibited moderate to severe symptoms at 
baseline (NCT02920021). It is difficult to conclusively inter-
pret the induction of immune tolerance with this number of 
patients. A recent phase IIa proof-of-concept trial for the treat-
ment of moderate to severe AD demonstrated that a single dose 
of etokimab led to decreased clinical severity (demonstrated by 
50% reduction of the eczema area and severity index [EASI] 
score 57 days after treatment). This was associated with a 
decrease in circulating eosinophils and IL-33–mediated IFN-γ 
release (NCT03533751) (116). Etokimab is currently also being 
investigated in phase II clinical trials for its effect on CRS with 
nasal polyps (NCT03614923) and severe eosinophilic asth-
ma (NCT03469934). MEDI3506 is currently being tested in a 
phase I trial for chronic obstructive pulmonary disease (COPD) 
(NCT03096795). The anti-ST2 drug candidate RG 6149/AMG 
282 has been tested in a phase I trial in CRS patients with nasal 
polyps, but no results have been published (NCT02170337). 
Moreover, recruitment for a phase II trial for treatment of COPD 
is ongoing (NCT03615040).
Given the potential functional redundancy of TSLP, IL-25, and 
IL-33 in the induction of Th2 responses, which is not caused by 
molecular or signaling pathway similarity, isolated neutralization 
of these molecules may fail to yield the desired clinical effect. In 
a murine model of helminth infection and chronic lung inflam-
mation, neutralizing TSLP, IL-25, or IL-33 individually did not 
prevent the development of Th2-dependent inflammation and 
fibrosis (117). Only simultaneous blockade of all three mediators 
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led to reductions in eosinophils, fibrosis, and ILC2s. Similar results 
were found in a model of house dust mite–induced allergic airway 
hypersensitivity (117). These data indicate that monotherapy tar-
geting individual cytokines may not be sufficient in certain cases of 
progressive type 2–driven disease, and combination therapy could 
be considered. While these preclinical studies targeting TSLP, 
IL-33, and IL-25 simultaneously showed a superior effect on the 
inhibition of Th2 responses, it should noted here that combination 
therapy with three new biologics in humans is currently not pos-
sible. The increased complexity associated with the use of combi-
nations of novel biologics may lead to unexpected side effects and 
increased toxicity. One innovative approach that is being pursued 
is the design of novel highly potent bispecific anti–TSLP/IL-13 anti-
bodies called Zweimabs (monovalent bispecific) and Doppelmabs 
(bivalent bispecific) that concurrently inhibit signaling by these 
two cytokines (118).
Targeting IgE and IgE-expressing B cells
Because of its key role in type I hypersensitivity reactions, IgE has 
always been a prime target for intervention in allergic disease. 
This has been approached from two different angles: (a) target-
ing soluble IgE and (b) targeting B cells that express surface IgE 
(119). Another less specific approach for targeting IgE production 
has been the depletion of all B cells using the anti-CD20 antibody 
rituximab (Figure 3).
Despite its critical role in allergies, surprisingly little is known 
regarding the regulation of IgE production in humans. This fact 
relates primarily to the extremely low frequency of IgE-switched 
memory B cells. It remains challenging to accurately detect and 
purify these cells from humans. A large body of research has con-
vincingly demonstrated that IgE production is highly dependent 
on Th2 responses, in particular IL-4 and IL-13 signaling (120). 
The main question that still remains incompletely answered per-
tains to the location of IgE memory. Which cells form the basis of 
IgE memory? This is a critical issue, because these cells should be 
targeted to efficiently eliminate allergen-specific IgE. There are 
three possible major cell types that could form a reservoir for the 
IgE memory response: (a) IgE-switched memory B cells, (b) long- 
living plasma cells that primarily reside in the bone marrow (121), 
and (c) memory B cells that switched to any isotype within the 
IgH (immunoglobulin heavy chain) locus located between IgHD 
and IgHE (in humans these are IgG3, IgG1, IgA1, IgG2, and IgG4, 
and in mice, IgG3, IgG1, IgG2b, and IgG2a), because these cells 
can develop into IgE-switched B cells through a process called 
sequential class switch recombination (122, 123). Our ability to 
design the optimal strategy for targeting IgE memory responses 
will strongly improve if we can define which IgH isotype is the 
major contributor to IgE memory.
Currently, omalizumab is the only efficacious IgE- targeting 
antibody licensed for the treatment of allergic asthma and 
chronic spontaneous urticaria (124–130). Preliminary data indi-
cate that patients suffering from systemic mastocytosis may also 
benefit from omalizumab treatment (131). Omalizumab binds 
soluble IgE, thereby preventing its binding to IgE receptors on 
effector cells (Figure 3). Interestingly, omalizumab treatment 
also leads to a reduction of FcεRI on mast cells, basophils, and 
DCs (132). Omalizumab is currently being tested for a wide 
range of allergic conditions and other pathologies (133). An 
additional anti-IgE antibody, ligelizumab (QGE031), that binds 
the Cε3 domain of IgE with higher affinity than omalizumab is 
currently in clinical testing (Figure 3). Ligelizumab was found to 
have a larger suppressive effect than omalizumab on circulating 
IgE, basophil FcεRI expression, and skin prick test responses 
to allergens (134). A controlled trial in 37 mild allergic asthma 
patients demonstrated that ligelizumab has greater efficacy than 
omalizumab against inhaled and skin allergic responses (135). 
However, both antibodies neutralize serum IgE without affecting 
IgE production by plasma cells. While this type of approach neu-
tralizes IgE-mediated type I hypersensitivity reactions, it has no 
impact on the IgE production, necessitating treatment at regular 
intervals of 2–4 weeks (125). Clinical studies are ongoing for 
urticaria (NCT03437278, NCT02649218).
An alternative strategy to interfere with IgE production involves 
the use of antibodies that bind to the membrane-bound form of 
IgE, thereby targeting B cells expressing an IgE B cell receptor 
(BCR). Quilizumab (MEMP1972A/RG7449) is a humanized mAb 
that binds to the M1′ segment of IgE (136). This segment is only 
present on membrane IgE and not on free, soluble IgE (137). There-
fore, quilizumab targets IgE+ memory B cells and plasmablasts, 
while long-lived IgE-switched plasma cells, which do not express 
surface IgE, are not targeted (Figure 3). Preclinical studies demon-
strated that targeting the M1′ domain of IgE efficiently reduced 
serum IgE without affecting other isotypes. Anti–M1′ domain 
was an effective prophylactic and therapeutic therapy in murine 
models of allergic asthma and helminth infection (136). Despite 
yielding a significant reduction of total and allergen- specific IgE, 
quilizumab treatment did not impact asthma exacerbations, lung 
function, and symptom scores in a phase II trial that included 578 
patients with inadequately controlled allergic asthma (138). Quili-
zumab reduced circulating IgE antibodies between 30% and 40%, 
while omalizumab treatment resulted in an 89% to 98% reduction 
(129). This indicates that targeting membrane IgE is not sufficient 
to remove the allergen-specific IgE to a degree that confers clini-
cal improvement. Therefore, other potential compartments of IgE 
memory appear to play a key role in the production of clinically rel-
evant, allergen-specific IgE. These may include long-living plasma 
cells or subpopulations of memory B cells of other isotypes that can 
undergo a secondary switch to IgE upon reactivation.
MEDI4212, another IgE-targeting biologic, binds to soluble 
and membrane IgE. The main potential advantage of this approach 
is that it may achieve an immediate clinical benefit by directly tar-
geting free IgE, while limiting the generation of new IgE-switched 
B cells and plasma cells (ref. 139 and Figure 3). In a phase I study, 
atopic individuals were treated with a single dose of MEDI4212, 
omalizumab, or placebo. MEDI4212 treatment decreased serum 
IgE more rapidly than omalizumab treatment, but IgE recovery was 
also much more rapid than in the omalizumab- treated group (140). 
The short-lived suppression of serum IgE in MEDI4212-treated 
patients corresponded with a rapid decrease in serum levels of the 
therapeutic antibody, a feature that limits the potential for dosing- 
schedule advantages over omalizumab.
A recent study showed that in a mouse model of peanut allergy 
and anaphylaxis, clinically relevant IgE titers were not sustained 
by long-living plasma cells but rather by allergen-specific memory 
The Journal of Clinical Investigation   R E V I E W  S E R I E S :  A L L E R G Y
1 4 5 9jci.org   Volume 129   Number 4   April 2019
 1. Akdis M, et al. Interleukins (from IL-1 to IL-38), 
interferons, transforming growth factor β, and 
TNF-α: receptors, functions, and roles in diseas-
es. J Allergy Clin Immunol. 2016;138(4):984–1010.
 2. van Neerven RJ, Knol EF, Ejrnaes A, Würtz-
en PA. IgE-mediated allergen presentation 
and blocking antibodies: regulation of T-cell 
activation in allergy. Int Arch Allergy Immunol. 
2006;141(2):119–129.
 3. Mudde GC, Bheekha R, Bruijnzeel-Koomen 
CA. IgE-mediated antigen presentation. Allergy. 
1995;50(3):193–199.
 4. Galli SJ, Tsai M, Piliponsky AM. The devel-
opment of allergic inflammation. Nature. 
2008;454(7203):445–454.
 5. Gerber BO, Pichler WJ. Cellular mechanisms of 
T cell mediated drug hypersensitivity. Curr Opin 
Immunol. 2004;16(6):732–737.
 6. Esteban-Gorgojo I, Antolín-Amérigo D, Domín-
guez-Ortega J, Quirce S. Non-eosinophilic 
asthma: current perspectives. J Asthma Allergy. 
2018;11:267–281.
 7. Muraro A, et al. Precision medicine in allergic 
disease—food allergy, drug allergy, and anaphy-
laxis—PRACTALL document of the European 
Academy of Allergy and Clinical Immunology 
and the American Academy of Allergy, Asthma 
and Immunology. Allergy. 2017;72(7):1006–1021.
 8. Muraro A, et al. Precision medicine in patients 
with allergic diseases: airway diseases and atopic 
dermatitis—PRACTALL document of the Euro-
pean Academy of Allergy and Clinical Immu-
nology and the American Academy of Allergy, 
Asthma & Immunology. J Allergy Clin Immunol. 
2016;137(5):1347–1358.
 9. Bachert C, Akdis CA. Phenotypes and emerging 
endotypes of chronic rhinosinusitis. J Allergy Clin 
Immunol Pract. 2016;4(4):621–628.
 10. Akdis CA, et al. Endotypes and phenotypes of 
chronic rhinosinusitis: a PRACTALL document 
of the European Academy of Allergy and Clinical 
Immunology and the American Academy of 
Allergy, Asthma & Immunology. J Allergy Clin 
Immunol. 2013;131(6):1479–1490.
 11. Agache I, Akdis C, Jutel M, Virchow JC.  
Untangling asthma phenotypes and endotypes. 
Allergy. 2012;67(7):835–846.
 12. Lötvall J, et al. Asthma endotypes: a new 
approach to classification of disease entities 
within the asthma syndrome. J Allergy Clin Immu-
nol. 2011;127(2):355–360.
 13. van de Veen W, Wirz OF, Globinska A, Akdis 
M. Novel mechanisms in immune tolerance to 
allergens during natural allergen exposure and 
allergen-specific immunotherapy. Curr Opin 
Immunol. 2017;48:74–81.
 14. Jutel M, et al. International Consensus on Aller-
gen Immunotherapy II: mechanisms, standard-
ization, and pharmacoeconomics. J Allergy Clin 
Immunol. 2016;137(2):358–368.
 15. Novak N, et al. Early suppression of basophil acti-
vation during allergen-specific immunotherapy 
by histamine receptor 2. J Allergy Clin Immunol. 
2012;130(5):1153–1158.e2.
 16. Akdis M, et al. Immune responses in healthy 
and allergic individuals are characterized by 
a fine balance between allergen-specific T 
regulatory 1 and T helper 2 cells. J Exp Med. 
2004;199(11):1567–1575.
 17. Jutel M, Van de Veen W, Agache I, Azkur KA, 
Akdis M, Akdis CA. Mechanisms of allergen-spe-
cific immunotherapy and novel ways for vaccine 
development. Allergol Int. 2013;62(4):425–433.
 18. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis 
CA, Akdis M. In vivo switch to IL-10-secreting T 
regulatory cells in high dose allergen exposure.  
J Exp Med. 2008;205(12):2887–2898.
 19. van de Veen W. The role of regulatory B cells in 
allergen immunotherapy. Curr Opin Allergy Clin 
Immunol. 2017;17(6):447–452.
 20. Boonpiyathad T, et al. High-dose bee venom 
fighting the itch response by targeting IL-31; and interfering with 
epithelium–immune cell interaction by targeting IL-25, IL-33, and 
TSLP, or by targeting soluble or cell surface–bound IgE. It should 
be noted here that downregulation of a general type 2 response 
may have certain consequences for immune responses in which 
Th2 cells, eosinophils, and type 2 effector cytokines such as IL-4, 
IL-5, and IL-13 play a role. Parasitic infections and downregulation 
and control of extensive type 1 immune responses that are domi-
nant in autoimmunity represent two main conditions that must be 
sorted out in multicenter studies. All of these effector molecules 
target upstream or downstream events in type 2 immune response, 
omitting only a fraction of patients who lack a predominant type 
2 immune response. Patients with non–type 2 response, such as 
intrinsic type of AD, non-eosinophilic asthma, CRS without nasal 
polyps, neutrophilic asthma, and obesity-induced asthma, have not 
so far been efficiently targeted with biologics. While there are obvi-
ous similarities, there are also evident clinical, immunological, and 
pathological divergences between asthma, allergic rhinitis, nasal 
polyps, food allergy, and EoE. Current approaches targeting type 
2 immunity seem to affect overlapping patient groups and produce 
similar final physiopathological outcomes. Extensive research in the 
area is needed, and given the rapid developments in such a short 
time, a brighter future is ahead for a variety of allergic diseases.
Acknowledgments
Funding is provided by the Center for Allergy Research and Educa-
tion (CARE) of Switzerland (to CK) and the Swiss National Science 
Foundation (grant 320030–159870, 310030_179428).
Address correspondence to: Mübeccel Akdis, Swiss Institute 
of Allergy and Asthma Research (SIAF), University of Zurich, 
Oberestrasse 22, CH-7270 Davos Platz, Switzerland. Phone: 
41.0.814100848; Email: akdism@siaf.uzh.ch.
B cells that replenish the IgE-switched plasma cell compartment 
(141). It remains to be determined whether the same applies to 
other models and how this finding translates to the human system. 
Notably, treating AD patients with the anti-CD20 antibody ritux-
imab, which depletes all circulating B cells (but only a fraction of 
B cells in various tissues), did not result in a reduction of allergen- 
specific IgE 4 to 8 weeks after treatment. This suggests that plasma 
cells can maintain IgE production for weeks to months without 
replenishment from circulating memory cells, or, alternatively, 
that tissue- resident memory B cells can replace circulating cells 
following depletion (142). Strategies that target these populations 
could be considered but may cause undesired side effects, because 
broadly targeting plasma cells or major memory B cell populations 
will impair protective humoral immunity against pathogens.
Conclusion
Allergies affect almost 1 billion people worldwide (143). A balance 
between immune tolerance and immune effector functions of 
innate and adaptive immune response has been shown to be deci-
sive in allergy development and treatment. Various models have 
been used to study the mechanisms of immune tolerance, including 
AIT in patients, beekeepers, and cat owners who are chronically 
exposed to high doses of allergens. In addition to allergy vaccines, 
strategies to induce immune tolerance, such as directed therapies that 
target specific mediators of allergic reactions, show great promise. 
Humanized antibodies that target essential cytokines, cytokine 
receptors, and soluble or membrane-bound IgE are promising 
approaches to the treatment of asthma, AD, allergic rhinitis, and 
food allergy, some of which are in clinical use. These approaches 
can be categorized by their modulation of type 2 immunity: tar-
geting the classical Th2 effector molecules by interfering with IL-4 
and IL-13; interfering with eosinophil responses by targeting IL-5; 
interfering with Th2 and mast cell responses by targeting IL-9; 
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